Quantum Biopharma Ltd. (NASDAQ:QNTM - Free Report) - Research analysts at Singular Research issued their Q1 2026 earnings per share estimates for shares of Quantum Biopharma in a note issued to investors on Wednesday, June 18th. Singular Research analyst G. Sriharan expects that the company will earn ($0.07) per share for the quarter. Singular Research currently has a "Moderate Buy" rating on the stock. The consensus estimate for Quantum Biopharma's current full-year earnings is ($3.27) per share. Singular Research also issued estimates for Quantum Biopharma's Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.53) EPS.
Quantum Biopharma (NASDAQ:QNTM - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($1.04). The firm had revenue of $2.09 million during the quarter, compared to analyst estimates of $2.09 million.
Separately, Wall Street Zen upgraded Quantum Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th.
View Our Latest Stock Analysis on QNTM
Quantum Biopharma Trading Up 16.0%
QNTM opened at $35.00 on Monday. Quantum Biopharma has a 12-month low of $2.70 and a 12-month high of $38.25. The business's fifty day simple moving average is $12.21 and its 200-day simple moving average is $7.84. The company has a market capitalization of $101.85 million, a price-to-earnings ratio of -2.19 and a beta of 0.54.
Institutional Investors Weigh In On Quantum Biopharma
An institutional investor recently raised its position in Quantum Biopharma stock. AdvisorShares Investments LLC raised its holdings in Quantum Biopharma Ltd. (NASDAQ:QNTM - Free Report) by 163.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 69,078 shares of the company's stock after buying an additional 42,845 shares during the quarter. AdvisorShares Investments LLC owned about 3.60% of Quantum Biopharma worth $254,000 at the end of the most recent reporting period. 1.24% of the stock is currently owned by institutional investors.
Quantum Biopharma Company Profile
(
Get Free Report)
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Quantum Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum Biopharma wasn't on the list.
While Quantum Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
